CAR T‐cell therapy for pancreatic cancer

Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenv...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of surgical oncology Ročník 116; číslo 1; s. 63 - 74
Hlavní autoři: DeSelm, Carl J., Tano, Zachary E., Varghese, Anna M., Adusumilli, Prasad S.
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Wiley Subscription Services, Inc 01.07.2017
Témata:
adoptive cell therapy
Antigens, Neoplasm - immunology
Cancer surgery
CAR T cells
Carcinoembryonic Antigen - immunology
CD24 Antigen - immunology
checkpoint blockade
chimeric antigen receptor
Clinical Trials as Topic
GPI-Linked Proteins - immunology
Humans
immunotherapy
Immunotherapy, Adoptive
Mesothelin
Mucin-1 - immunology
Neoplasm Proteins - immunology
Pancreatic cancer
Pancreatic Neoplasms - immunology
Pancreatic Neoplasms - therapy
Receptor, ErbB-2 - immunology
Receptors, Antigen, T-Cell
Receptors, Natural Killer Cell - immunology
Stromal Cells - immunology
T-Lymphocytes - immunology
T-Lymphocytes - transplantation
Transplantation Conditioning
checkpoint blockade
chimeric antigen receptor
CAR T cells
adoptive cell therapy
immunotherapy
ISSN:0022-4790, 1096-9098, 1096-9098
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T‐cell therapy.
AbstractList Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.
Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.
Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient’s own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells poses hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.
Author Tano, Zachary E.
Varghese, Anna M.
Adusumilli, Prasad S.
DeSelm, Carl J.
AuthorAffiliation 1 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
2 Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
3 Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center
AuthorAffiliation_xml – name: 1 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
– name: 2 Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
– name: 3 Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center
Author_xml – sequence: 1
  givenname: Carl J.
  surname: DeSelm
  fullname: DeSelm, Carl J.
  organization: Memorial Sloan Kettering Cancer Center
– sequence: 2
  givenname: Zachary E.
  surname: Tano
  fullname: Tano, Zachary E.
  organization: Memorial Sloan Kettering Cancer Center
– sequence: 3
  givenname: Anna M.
  surname: Varghese
  fullname: Varghese, Anna M.
  organization: Memorial Sloan Kettering Cancer Center
– sequence: 4
  givenname: Prasad S.
  orcidid: 0000-0002-1699-2046
  surname: Adusumilli
  fullname: Adusumilli, Prasad S.
  email: adusumip@mskcc.org
  organization: Memorial Sloan Kettering Cancer Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28346697$$D View this record in MEDLINE/PubMed
BookMark eNp1kc9OGzEQxq0qVUmgB16gWqkXqLTJ2Ou11xekKALaCgkJcre8zixstFmn9gaUG4_AM_ZJ6jQBlaic_Gd-8-mb-Qak17oWCTmmMKQAbDQPbsi4YPID6VNQIlWgih7pxxpLuVRwQAYhzAFAKcE_kQNWZFwIJfvk22R8k0x_Pz1bbJqku0dvluukcj5ZmtZ6NF1tExuv6I_Ix8o0AT_vzkMyvTifTr6nV9eXPybjq9Rynsk0zwpeWgBZCESIPwLKApBZZau8hEpUM4Woyll8MaGgip4EE2CAZTml2SE528ouV-UCZxbbzptGL329MH6tnan120pb3-s796BzrmgmNgInOwHvfq0wdHpRh814pkW3CpoWBZWSgxQR_bqHzt3Kt3E6TRXluYy-IFJf_nX0auVlixEYbQHrXQgeK23rLm7ObQzWjaagNznpmJP-m1PsON3reBH9H7tTf6wbXL8P6p-319uOPwj7oHI
CitedBy_id crossref_primary_10_3748_wjg_v27_i24_3568
crossref_primary_10_1016_j_jtho_2025_08_015
crossref_primary_10_1051_e3sconf_202127103065
crossref_primary_10_3390_cancers12082274
crossref_primary_10_1016_j_biopha_2025_118308
crossref_primary_10_1016_j_canlet_2025_217699
crossref_primary_10_1016_j_ctarc_2018_08_001
crossref_primary_10_3390_ijms18061231
crossref_primary_10_1016_j_ctarc_2018_08_002
crossref_primary_10_1016_j_ctrv_2017_08_007
crossref_primary_10_3390_ijms24043559
crossref_primary_10_3390_cancers17172898
crossref_primary_10_1016_j_hbpd_2021_08_012
crossref_primary_10_1016_j_addr_2025_115671
crossref_primary_10_3390_jcm10040566
crossref_primary_10_1007_s10620_020_06183_9
crossref_primary_10_3390_cancers17071246
crossref_primary_10_1016_j_lpm_2019_02_031
crossref_primary_10_1038_s41571_019_0281_6
crossref_primary_10_3390_cancers15051357
crossref_primary_10_1002_jso_24672
crossref_primary_10_1002_cam4_2430
crossref_primary_10_1007_s11523_018_0567_0
crossref_primary_10_1016_j_seminoncol_2025_152411
crossref_primary_10_3390_magnetochemistry7050058
crossref_primary_10_3389_fimmu_2024_1287459
crossref_primary_10_4251_wjgo_v15_i10_1691
crossref_primary_10_1016_j_bbcan_2020_188387
crossref_primary_10_1016_j_coi_2018_03_002
crossref_primary_10_3390_biomedicines9040389
crossref_primary_10_1016_j_actbio_2022_12_013
crossref_primary_10_3390_cancers13195028
crossref_primary_10_3390_cancers15082327
crossref_primary_10_1016_j_surg_2017_10_056
crossref_primary_10_1080_02652048_2022_2111472
crossref_primary_10_1089_cbr_2021_0317
crossref_primary_10_3389_fimmu_2023_1105265
crossref_primary_10_1097_CM9_0000000000001216
crossref_primary_10_1155_2021_5549298
crossref_primary_10_1016_j_biopha_2020_110562
crossref_primary_10_3389_fonc_2020_00382
crossref_primary_10_1186_s12943_023_01775_1
crossref_primary_10_1016_j_ymthe_2018_09_008
crossref_primary_10_1186_s12920_020_00868_w
crossref_primary_10_1097_MPA_0000000000002277
crossref_primary_10_1097_MPA_0000000000000970
crossref_primary_10_2174_012212697X366863250331152051
crossref_primary_10_1016_j_ymthe_2025_01_012
crossref_primary_10_3390_ijms252111560
crossref_primary_10_3389_fimmu_2018_01878
crossref_primary_10_1098_rsob_200004
crossref_primary_10_3389_fimmu_2020_00611
crossref_primary_10_3390_jcm9010182
crossref_primary_10_1016_j_omto_2023_08_007
crossref_primary_10_1007_s12029_020_00457_1
crossref_primary_10_21926_obm_genet_2403252
crossref_primary_10_1186_s13046_019_1153_8
crossref_primary_10_3390_cancers10010006
crossref_primary_10_1186_s12943_020_01151_3
crossref_primary_10_3390_ijms19113415
Cites_doi 10.1056/NEJMoa1011923
10.1016/j.ejca.2007.08.028
10.1016/j.ccr.2005.10.018
10.1056/NEJMoa1407222
10.1158/0008-5472.CAN-13-3723
10.1158/1078-0432.CCR-13-1862
10.1158/1078-0432.CCR-05-0596
10.1126/scitranslmed.3010162
10.1172/JCI83092
10.1074/jbc.M806776200
10.1097/00000421-200110000-00016
10.1007/s00534-006-1166-5
10.1084/jem.20031435
10.1016/j.jss.2009.05.026
10.1073/pnas.0813101106
10.1158/2326-6066.CIR-13-0008
10.1016/j.jcyt.2016.07.003
10.1016/j.lungcan.2005.03.020
10.1097/CJI.0b013e3182829903
10.1111/j.1752-8062.2008.00070.x
10.1158/2159-8290.CD-15-0583
10.1245/s10434-013-3390-y
10.1371/journal.pone.0040157
10.1097/MPA.0b013e318221bed8
10.1177/1758834014564775
10.1038/bjc.2013.32
10.1038/mto.2016.11
10.1016/j.ccr.2005.10.012
10.1158/0008-5472.CAN-14-2921
10.1200/JCO.2014.56.2025
10.1084/jem.20130110
10.1038/srep01870
10.1158/2326-6066.CIR-13-0170
10.1158/1541-7786.MCR-11-0023
10.1038/35059110
10.1016/j.immuni.2016.05.014
10.1158/0008-5472.CAN-14-0155
10.1016/S0140-6736(15)00986-1
10.1093/ajcp/90.1.17
10.1126/scitranslmed.3008226
10.1056/NEJMoa1215134
10.1002/pros.23214
10.1136/jcp.39.6.610
10.1158/1078-0432.CCR-06-0369
10.1126/scitranslmed.3006682
10.1080/2162402X.2016.1273302
10.1073/pnas.1417636112
10.1158/0008-5472.CAN-11-3850
10.1111/cas.12119
10.1007/s002620050254
10.1097/CJI.0b013e3181ee6675
10.1158/0008-5472.CAN-07-0175
10.1016/j.cellimm.2015.02.003
10.1053/j.gastro.2012.07.017
10.1056/NEJMoa1304369
10.4049/jimmunol.173.4.2392
10.1182/blood-2011-04-348540
10.1182/blood-2010-07-294520
10.1172/JCI80010
10.1593/neo.11980
10.1182/blood-2011-05-354449
10.1158/0008-5472.CAN-14-3041
10.1038/mt.2009.210
10.1007/s10875-012-9689-9
10.1038/nature14292
10.3389/fonc.2014.00325
10.1097/MOG.0b013e328363affe
10.3390/ph8020230
10.1089/hum.2013.209
10.1158/1078-0432.CCR-13-0458
10.1016/j.ccell.2015.09.022
10.1158/1078-0432.CCR-11-0351
10.1182/blood-2011-10-384388
10.1158/2159-8290.CD-12-0548
10.1097/00006676-200401000-00023
10.1074/jbc.M312372200
10.1038/nm0296-216
10.1016/j.ejso.2009.02.013
10.1042/BST20150291
10.1111/j.1349-7006.2012.02214.x
10.1371/journal.pone.0070417
10.1038/nbt0102-70
10.1038/nbt.2459
10.1002/path.1027
10.13075/ijomeh.1896.00637
10.1158/0008-5472.CAN-14-0337
10.1097/MD.0000000000005541
10.1084/jem.20082492
10.1007/s00262-008-0523-4
10.1172/JCI85309
10.1016/S1470-2045(16)00078-4
10.1038/sj.onc.1203426
10.1016/j.ctrv.2016.01.004
10.1038/nm730
10.1371/journal.pone.0007234
10.1182/blood-2013-06-506741
10.1371/journal.pone.0114900
10.1038/ajg.2016.288
10.1158/1541-7786.MCR-07-0254
10.1159/000217555
10.1158/1078-0432.CCR-07-0869
10.1126/science.1076514
10.1111/j.1349-7006.2007.00715.x
10.1016/j.biopha.2006.06.006
10.1158/1078-0432.CCR-11-2614
10.1007/s00262-012-1324-3
10.18632/oncotarget.1919
10.1038/mt.2010.24
10.1164/rccm.200802-258OC
10.1158/0008-5472.CAN-06-2030
10.1158/1078-0432.CCR-09-3169
10.1097/SLA.0b013e3181fd271c
10.4251/wjgo.v8.i11.786
10.1084/jem.20101876
10.1159/000007488
10.1309/F1B64CL7H8VJKEAF
10.1158/2326-6066.CIR-13-0006
10.1016/j.bbrc.2010.11.040
10.1126/scitranslmed.3006597
10.1182/blood-2009-03-209650
10.1053/j.gastro.2012.06.037
10.1111/j.1349-7006.2012.02411.x
10.1038/mto.2016.28
10.1038/nm.3833
10.1111/j.1349-7006.2009.01176.x
10.1111/j.1477-2574.2011.00344.x
10.1111/cas.12332
10.1371/journal.pone.0096565
10.1007/s10555-013-9439-3
10.1038/mt.2013.17
10.4161/onci.27614
10.1016/j.ccr.2012.01.007
10.1038/sj.bjc.6602232
10.4049/jimmunol.182.3.1746
10.1158/1541-7786.MCR-08-0095
10.1097/01.mpa.0000173459.81193.4d
10.1038/nm.1882
10.4049/jimmunol.1301523
10.1073/pnas.86.24.10024
10.1111/imr.12132
10.1126/science.aab4077
ContentType Journal Article
Copyright 2017 Wiley Periodicals, Inc.
Copyright_xml – notice: 2017 Wiley Periodicals, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
5PM
DOI 10.1002/jso.24627
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1096-9098
EndPage 74
ExternalDocumentID PMC5491361
28346697
10_1002_jso_24627
JSO24627
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: National Cancer Institute
  funderid: P30‐CA008748
– fundername: Stand Up To Cancer
  funderid: SU2C‐AACR‐DT1012
– fundername: Congressionally Directed Medical Research Programs
  funderid: BC132124; LC110202; PR101053
– fundername: Memorial Sloan‐Kettering Cancer Center
  funderid: GC228760
– fundername: NCI NIH HHS
  grantid: P30 CA008748
– fundername: NCI NIH HHS
  grantid: T32 CA009501
GroupedDBID ---
.3N
.GA
05W
0R~
10A
1L6
1OB
1OC
1ZS
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIAGR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FUBAC
G-S
G.N
GODZA
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
ROL
RX1
RYL
SUPJJ
SV3
TEORI
UB1
V2E
V8K
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WVDHM
WXI
WXSBR
XG1
XPP
XV2
ZZTAW
~IA
~WT
.55
.GJ
.Y3
31~
3O-
53G
AANHP
AAQQT
AAYXX
ABEML
ACBWZ
ACRPL
ACSCC
ACYXJ
ADNMO
AFFNX
AGQPQ
AIQQE
ASPBG
AVWKF
AZFZN
BDRZF
CITATION
FEDTE
GLUZI
HF~
HVGLF
M6P
O8X
PALCI
RIWAO
RJQFR
SAMSI
X7M
ZGI
ZXP
AAHHS
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
5PM
ID FETCH-LOGICAL-c4437-5384bc00786ee043760b80e2c9cf5b0f6fd9ee9bdf5b2690f9966260a0235113
IEDL.DBID DRFUL
ISICitedReferencesCount 72
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000404555200008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0022-4790
1096-9098
IngestDate Tue Nov 04 01:58:54 EST 2025
Thu Oct 02 10:59:46 EDT 2025
Sat Nov 29 14:38:48 EST 2025
Thu Apr 03 07:07:58 EDT 2025
Sat Nov 29 05:16:53 EST 2025
Tue Nov 18 22:01:38 EST 2025
Sun Sep 21 06:17:44 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords checkpoint blockade
chimeric antigen receptor
CAR T cells
adoptive cell therapy
immunotherapy
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#am
http://onlinelibrary.wiley.com/termsAndConditions#vor
2017 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4437-5384bc00786ee043760b80e2c9cf5b0f6fd9ee9bdf5b2690f9966260a0235113
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-1699-2046
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/5491361
PMID 28346697
PQID 1914572600
PQPubID 1016364
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5491361
proquest_miscellaneous_1881774076
proquest_journals_1914572600
pubmed_primary_28346697
crossref_citationtrail_10_1002_jso_24627
crossref_primary_10_1002_jso_24627
wiley_primary_10_1002_jso_24627_JSO24627
PublicationCentury 2000
PublicationDate July 1, 2017
PublicationDateYYYYMMDD 2017-07-01
PublicationDate_xml – month: 07
  year: 2017
  text: July 1, 2017
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Journal of surgical oncology
PublicationTitleAlternate J Surg Oncol
PublicationYear 2017
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2004; 200
2013; 3
2010; 16
2011; 118
2013; 1
2011; 117
2010; 18
2004; 28
2013; 369
2015; 75
2013; 62
2013; 368
2016; 387
2013; 122
2014; 25
2009; 113
2012; 18
2014; 371
2013; 8
2013; 5
2014; 257
2014; 21
2014; 20
2001; 61
2000; 19
2004; 173
1
2013; 191
2007; 67
2012; 21
2011; 364
2016; 44
2010; 33
2013; 108
2015; 125
2009; 182
2015; 520
2013; 104
2002; 8
2016; 95
2016; 18
2012; 103
1988; 90
2016; 17
2001; 24
2007; 13
2012; 32
2007; 14
2011; 253
2011; 9
2015; 350
2016; 6
2004; 279
2016; 3
2005; 124
2013; 73
2005; 8
2015; 112
2009; 100
2013; 210
2008; 44
2016; 29
2016; 8
2005; 11
2012; 119
2009; 106
2013; 29
2017; 6
1989; 86
2013; 21
2002; 196
2015; 33
2016; 76
1986; 39
2011; 13
2008; 6
2011; 17
2013; 19
2015; 294
2006; 60
1998; 59
2009; 58
2014; 5
2011; 208
2014; 4
2014; 3
2014; 2
2005; 31
2016; 111
2009; 284
2014; 9
2009; 206
1996; 2
2014; 6
2011; 167
2012; 143
2006; 12
2010
2010; 403
2002; 298
2011; 40
2008; 14
2001; 409
2008; 99
2016; 126
2005; 49
2004; 91
2015; 8
2015; 7
2014; 105
2009; 35
2015; 28
2013; 36
2002; 20
1988; 9
2013; 32
2013; 31
2015; 21
2016
2009; 4
2014; 74
2008; 178
2012; 7
1996; 42
e_1_2_10_21_1
e_1_2_10_44_1
e_1_2_10_40_1
e_1_2_10_109_1
e_1_2_10_131_1
e_1_2_10_70_1
e_1_2_10_93_1
e_1_2_10_2_1
e_1_2_10_139_1
e_1_2_10_18_1
e_1_2_10_74_1
e_1_2_10_97_1
e_1_2_10_116_1
e_1_2_10_6_1
e_1_2_10_55_1
e_1_2_10_135_1
e_1_2_10_14_1
e_1_2_10_37_1
e_1_2_10_78_1
e_1_2_10_112_1
e_1_2_10_13_1
Seo YD (e_1_2_10_113_1) 2016
e_1_2_10_32_1
e_1_2_10_51_1
e_1_2_10_120_1
e_1_2_10_147_1
e_1_2_10_82_1
e_1_2_10_128_1
e_1_2_10_29_1
e_1_2_10_63_1
e_1_2_10_86_1
e_1_2_10_105_1
e_1_2_10_124_1
e_1_2_10_25_1
e_1_2_10_48_1
e_1_2_10_67_1
e_1_2_10_101_1
e_1_2_10_143_1
e_1_2_10_45_1
e_1_2_10_22_1
e_1_2_10_41_1
e_1_2_10_132_1
e_1_2_10_90_1
e_1_2_10_71_1
e_1_2_10_117_1
e_1_2_10_94_1
e_1_2_10_52_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_75_1
e_1_2_10_136_1
e_1_2_10_38_1
e_1_2_10_98_1
e_1_2_10_56_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_121_1
e_1_2_10_144_1
e_1_2_10_60_1
e_1_2_10_106_1
e_1_2_10_129_1
e_1_2_10_83_1
e_1_2_10_64_1
e_1_2_10_102_1
e_1_2_10_125_1
e_1_2_10_140_1
e_1_2_10_49_1
e_1_2_10_87_1
e_1_2_10_26_1
e_1_2_10_68_1
e_1_2_10_23_1
e_1_2_10_46_1
e_1_2_10_69_1
e_1_2_10_42_1
e_1_2_10_110_1
e_1_2_10_91_1
e_1_2_10_72_1
e_1_2_10_95_1
e_1_2_10_118_1
e_1_2_10_4_1
e_1_2_10_53_1
e_1_2_10_137_1
e_1_2_10_16_1
e_1_2_10_39_1
e_1_2_10_76_1
e_1_2_10_99_1
Argani P (e_1_2_10_79_1) 2001; 61
e_1_2_10_114_1
e_1_2_10_8_1
e_1_2_10_57_1
e_1_2_10_133_1
e_1_2_10_58_1
e_1_2_10_34_1
e_1_2_10_11_1
e_1_2_10_30_1
e_1_2_10_119_1
e_1_2_10_145_1
e_1_2_10_80_1
e_1_2_10_61_1
e_1_2_10_84_1
e_1_2_10_107_1
e_1_2_10_126_1
e_1_2_10_27_1
e_1_2_10_65_1
e_1_2_10_88_1
e_1_2_10_103_1
e_1_2_10_141_1
e_1_2_10_122_1
e_1_2_10_24_1
e_1_2_10_43_1
e_1_2_10_20_1
e_1_2_10_108_1
e_1_2_10_130_1
e_1_2_10_92_1
e_1_2_10_73_1
e_1_2_10_115_1
e_1_2_10_138_1
e_1_2_10_96_1
e_1_2_10_54_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_77_1
e_1_2_10_111_1
e_1_2_10_134_1
e_1_2_10_36_1
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_59_1
e_1_2_10_31_1
e_1_2_10_50_1
e_1_2_10_146_1
e_1_2_10_81_1
e_1_2_10_62_1
e_1_2_10_104_1
e_1_2_10_127_1
e_1_2_10_85_1
e_1_2_10_28_1
e_1_2_10_66_1
e_1_2_10_100_1
e_1_2_10_123_1
e_1_2_10_142_1
e_1_2_10_47_1
e_1_2_10_89_1
References_xml – volume: 103
  start-page: 739
  year: 2012
  end-page: 746
  article-title: Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma
  publication-title: Cancer Sci
– volume: 39
  start-page: 610
  year: 1986
  end-page: 614
  article-title: Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry
  publication-title: J Clin Pathol
– volume: 173
  start-page: 2392
  year: 2004
  end-page: 2401
  article-title: Membrane‐associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46
  publication-title: J Immunol
– volume: 178
  start-page: 832
  year: 2008
  end-page: 837
  article-title: Soluble mesothelin‐related protein in an asbestos‐exposed population: the dust diseases board cohort study
  publication-title: Am J Respir Crit Care Med
– volume: 8
  start-page: e70417
  year: 2013
  article-title: Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression
  publication-title: PLoS ONE
– volume: 14
  start-page: 224
  year: 2007
  end-page: 232
  article-title: Molecular genetics of pancreatic intraepithelial neoplasia
  publication-title: J Hepatobiliary Pancreat Surg
– volume: 62
  start-page: 225
  year: 2013
  end-page: 236
  article-title: Rosiglitazone and gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer
  publication-title: Cancer Immunol Immunother
– volume: 18
  start-page: 413
  year: 2010
  end-page: 420
  article-title: Chimeric antigen receptors combining 4‐1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl‐XL activation and CD8+ T cell‐mediated tumor eradication
  publication-title: Mol Ther
– volume: 167
  start-page: e211
  year: 2011
  end-page: e219
  article-title: Significance of M2‐polarized tumor‐associated macrophage in pancreatic cancer
  publication-title: J Surg Res
– volume: 6
  start-page: 151
  year: 2014
  article-title: Regional delivery of mesothelin‐targeted CAR T cell therapy generates potent and long‐lasting CD4‐dependent tumor immunity
  publication-title: Sci Transl Med
– volume: 12
  start-page: 5423
  year: 2006
  end-page: 5434
  article-title: Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions
  publication-title: Clin Cancer Res
– volume: 3
  start-page: 1870
  year: 2013
  article-title: Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP‐7 activation
  publication-title: Sci Rep
– volume: 8
  start-page: 230
  year: 2015
  end-page: 249
  article-title: Seatbelts in CAR therapy: how safe are CARS
  publication-title: Pharmaceuticals (Basel)
– volume: 1
  start-page: 43
  year: 2013
  end-page: 53
  article-title: Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo
  publication-title: Cancer Immunol Res
– volume: 117
  start-page: 72
  year: 2011
  end-page: 82
  article-title: Immune responses to transgene and retroviral vector in patients treated with ex vivo‐engineered T cells
  publication-title: Blood
– volume: 3
  start-page: 16011
  year: 2016
  article-title: Toxicity and management in CAR T‐cell therapy
  publication-title: Mol Ther Oncolytics
– volume: 59
  start-page: 192
  year: 1998
  end-page: 198
  article-title: Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma
  publication-title: Digestion
– volume: 40
  start-page: 1276
  year: 2011
  end-page: 1282
  article-title: Co‐expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma
  publication-title: Pancreas
– volume: 99
  start-page: 590
  year: 2008
  end-page: 594
  article-title: Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells
  publication-title: Cancer Sci
– volume: 119
  start-page: 2709
  year: 2012
  end-page: 2720
  article-title: B‐cell depletion and remissions of malignancy along with cytokine‐associated toxicity in a clinical trial of anti‐CD19 chimeric‐antigen‐receptor‐transduced T cells
  publication-title: Blood
– volume: 3
  start-page: e27614
  year: 2014
  article-title: Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
  publication-title: Oncoimmunology
– volume: 44
  start-page: 412
  year: 2016
  end-page: 418
  article-title: Armored CAR T‐cells: utilizing cytokines and pro‐inflammatory ligands to enhance CAR T‐cell anti‐tumour efficacy
  publication-title: Biochem Soc Trans
– volume: 284
  start-page: 3739
  year: 2009
  end-page: 3749
  article-title: A binding domain on mesothelin for CA125/MUC16
  publication-title: J Biol Chem
– volume: 74
  start-page: 2913
  year: 2014
  end-page: 2921
  article-title: Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States
  publication-title: Cancer Res
– volume: 113
  start-page: 6392
  year: 2009
  end-page: 6402
  article-title: T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
  publication-title: Blood
– volume: 49
  start-page: S109
  year: 2005
  end-page: S111
  article-title: Soluble mesothelin‐related protein—a blood test for mesothelioma
  publication-title: Lung Cancer
– volume: 35
  start-page: 1098
  year: 2009
  end-page: 1104
  article-title: HER‐family gene amplification and expression in resected pancreatic cancer
  publication-title: Eur J Surg Oncol
– volume: 61
  start-page: 4320
  year: 2001
  end-page: 4324
  article-title: Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma
  publication-title: Cancer Res
– volume: 257
  start-page: 56
  year: 2014
  end-page: 71
  article-title: Exploiting the curative potential of adoptive T‐cell therapy for cancer
  publication-title: Immunol Rev
– volume: 7
  start-page: 68
  year: 2015
  end-page: 84
  article-title: Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies
  publication-title: Ther Adv Med Oncol
– volume: 11
  start-page: 6342
  year: 2005
  end-page: 6351
  article-title: Identification of novel human CTL epitopes and their agonist epitopes of mesothelin
  publication-title: Clin Cancer Res
– volume: 143
  start-page: 1375.e1371
  year: 2012
  end-page: 1384.e1375
  article-title: Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice
  publication-title: Gastroenterology
– volume: 182
  start-page: 1746
  year: 2009
  end-page: 1755
  article-title: Disruption of CCR5‐dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer
  publication-title: J Immunol
– volume: 143
  start-page: 1095.e2
  year: 2012
  end-page: 1107.e2
  article-title: T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice
  publication-title: Gastroenterology
– volume: 350
  start-page: 4077
  year: 2015
  article-title: Remote control of therapeutic T cells through a small molecule‐gated chimeric receptor
  publication-title: Science
– volume: 18
  start-page: 1393
  year: 2016
  end-page: 1409
  article-title: Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells
  publication-title: Cytotherapy
– volume: 74
  start-page: 2907
  year: 2014
  end-page: 2912
  article-title: Discovery of mesothelin and exploiting it as a target for immunotherapy
  publication-title: Cancer Res
– volume: 33
  start-page: 780
  year: 2010
  end-page: 788
  article-title: Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b
  publication-title: J Immunother
– volume: 2
  start-page: 216
  year: 1996
  end-page: 223
  article-title: T‐cell mediated rejection of gene‐modified HIV‐specific cytotoxic T lymphocytes in HIV‐infected patients
  publication-title: Nat Med
– volume: 44
  start-page: 1444
  year: 2016
  end-page: 1454
  article-title: Engineered CAR T cells targeting the cancer‐associated Tn‐glycoform of the membrane mucin MUC1 control adenocarcinoma
  publication-title: Immunity
– year: 2010
– volume: 125
  start-page: 3392
  year: 2015
  end-page: 3400
  article-title: CAR therapy: the CD19 paradigm
  publication-title: J Clin Invest
– volume: 105
  start-page: 159
  year: 2014
  end-page: 167
  article-title: Suppression of Tregs by anti‐glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon‐alpha gene therapy for pancreatic cancer
  publication-title: Cancer Sci
– volume: 33
  start-page: 540
  year: 2015
  end-page: 549
  article-title: Chemotherapy‐refractory diffuse large B‐cell lymphoma and indolent B‐cell malignancies can be effectively treated with autologous T cells expressing an anti‐CD19 chimeric antigen receptor
  publication-title: J Clin Oncol
– volume: 67
  start-page: 1030
  year: 2007
  end-page: 1037
  article-title: Identification of pancreatic cancer stem cells
  publication-title: Cancer Res
– volume: 1
  start-page: 228
  end-page: 239
  article-title: Effective depletion of regulatory T cells allows the recruitment of mesothelin‐specific CD8 T cells to the antitumor immune response against a mesothelin‐expressing mouse pancreatic adenocarcinoma
  publication-title: Clin Transl Sci
– volume: 106
  start-page: 3360
  year: 2009
  end-page: 3365
  article-title: Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
  publication-title: Proc Natl Acad Sci USA
– volume: 6
  start-page: 224ra225
  year: 2014
  article-title: Efficacy and toxicity management of 19‐28z CAR T cell therapy in B cell acute lymphoblastic leukemia
  publication-title: Sci Transl Med
– volume: 9
  start-page: 114900
  year: 2014
  article-title: Mesothelin expression in triple negative breast carcinomas correlates significantly with basal‐like phenotype, distant metastases and decreased survival
  publication-title: PLoS ONE
– volume: 14
  start-page: 1264
  year: 2008
  end-page: 1270
  article-title: Virus‐specific T cells engineered to coexpress tumor‐specific receptors: persistence and antitumor activity in individuals with neuroblastoma
  publication-title: Nat Med
– volume: 122
  start-page: 2965
  year: 2013
  end-page: 2973
  article-title: Infusion of donor‐derived CD19‐redirected virus‐specific T cells for B‐cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
  publication-title: Blood
– volume: 21
  start-page: 904
  year: 2013
  end-page: 912
  article-title: Treatment of metastatic renal cell carcinoma with CAIX CAR‐engineered T cells: clinical evaluation and management of on‐target toxicity
  publication-title: Mol Ther
– volume: 279
  start-page: 9190
  year: 2004
  end-page: 9198
  article-title: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
  publication-title: J Biol Chem
– volume: 95
  start-page: e5541
  year: 2016
  article-title: Role of immune cells in pancreatic cancer from bench to clinical application: an updated review
  publication-title: Medicine
– volume: 103
  start-page: 2012
  year: 2012
  end-page: 2020
  article-title: Impact of tumor‐associated macrophages on invasive ductal carcinoma of the pancreas head
  publication-title: Cancer Sci
– volume: 208
  start-page: 469
  year: 2011
  end-page: 478
  article-title: Intratumor T helper type 2 cell infiltrate correlates with cancer‐associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer
  publication-title: J Exp Med
– volume: 9
  start-page: 1294
  year: 2011
  end-page: 1304
  article-title: MT1‐MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF‐beta signaling
  publication-title: Mol Cancer Res
– volume: 31
  start-page: 71
  year: 2013
  end-page: 75
  article-title: Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
  publication-title: Nat Biotechnol
– volume: 73
  start-page: 1709
  year: 2013
  end-page: 1720
  article-title: Therapeutic efficacy of bifunctional siRNA combining TGF‐beta1 silencing with RIG‐I activation in pancreatic cancer
  publication-title: Cancer Res
– volume: 29
  start-page: 395
  year: 2016
  end-page: 404
  article-title: Validity of mesothelin in occupational medicine practice
  publication-title: Int J Occup Med Environ Health
– volume: 126
  start-page: 3130
  year: 2016
  end-page: 3144
  article-title: Human CAR T cells with cell‐intrinsic PD‐1 checkpoint blockade resist tumor‐mediated inhibition
  publication-title: J Clin Invest
– volume: 49
  start-page: S109
  year: 2005
  end-page: S111
  article-title: Soluble mesothelin‐related protein‐a blood test for mesothelioma
  publication-title: Lung Cancer
– volume: 8
  start-page: 369
  year: 2005
  end-page: 380
  article-title: TGF‐beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
  publication-title: Cancer Cell
– volume: 20
  start-page: 1020
  year: 2014
  end-page: 1028
  article-title: Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence‐free and overall survival in early‐stage lung adenocarcinoma
  publication-title: Clin Cancer Res
– volume: 16
  start-page: 3533
  year: 2010
  end-page: 3538
  article-title: Prostate stem cell antigen: a Jekyll and Hyde molecule
  publication-title: Clin Cancer Res
– volume: 409
  start-page: 1055
  year: 2001
  end-page: 1060
  article-title: Recognition of haemagglutinins on virus‐infected cells by NKp46 activates lysis by human NK cells
  publication-title: Nature
– volume: 7
  start-page: 40157
  year: 2012
  article-title: A novel survival‐based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers
  publication-title: PLoS ONE
– volume: 42
  start-page: 71
  year: 1996
  end-page: 80
  article-title: The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine
  publication-title: Cancer Immunol Immunother
– volume: 44
  start-page: 17
  year: 2016
  end-page: 25
  article-title: Changing the course of pancreatic cancer? Focus on recent translational advances
  publication-title: Cancer Treat Rev
– volume: 13
  start-page: 1093
  year: 2011
  end-page: 1100
  article-title: Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma
  publication-title: Neoplasia
– volume: 371
  start-page: 1507
  year: 2014
  end-page: 1517
  article-title: Chimeric antigen receptor T cells for sustained remissions in leukemia
  publication-title: N Engl J Med
– volume: 13
  start-page: 5144
  year: 2007
  end-page: 5149
  article-title: Phase I study of SS1P, a recombinant anti‐mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin‐expressing mesothelioma, ovarian, and pancreatic cancers
  publication-title: Clin Cancer Res
– volume: 21
  start-page: 670
  year: 2014
  end-page: 676
  article-title: Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma
  publication-title: Ann Surg Oncol
– volume: 32
  start-page: 1059
  year: 2012
  end-page: 1070
  article-title: Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling
  publication-title: J Clin Immunol
– volume: 21
  start-page: 418
  year: 2012
  end-page: 429
  article-title: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma
  publication-title: Cancer cell
– volume: 294
  start-page: 54
  year: 2015
  end-page: 59
  article-title: Using chemo‐drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer
  publication-title: Cell Immunol
– volume: 520
  start-page: 373
  year: 2015
  end-page: 377
  article-title: Radiation and dual checkpoint blockade activate non‐redundant immune mechanisms in cancer
  publication-title: Nature
– volume: 4
  start-page: e7234
  year: 2009
  article-title: Non‐redundant role for IL‐12 and IL‐27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients
  publication-title: PLoS ONE
– volume: 25
  start-page: 1003
  year: 2014
  end-page: 1012
  article-title: A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer
  publication-title: Hum Gene Ther
– volume: 75
  start-page: 2800
  year: 2015
  end-page: 2810
  article-title: Tumor‐promoting desmoplasia is disrupted by depleting FAP‐expressing stromal cells
  publication-title: Cancer Res
– volume: 13
  start-page: 643
  year: 2011
  end-page: 650
  article-title: Engineered T cells for pancreatic cancer treatment
  publication-title: HPB (Oxford)
– volume: 6
  start-page: 133
  year: 2016
  end-page: 146
  article-title: Mesothelin‐targeted CARs: driving T Cells to solid tumors
  publication-title: Cancer Discov
– volume: 32
  start-page: 585
  year: 2013
  end-page: 602
  article-title: Stromal expression of SPARC in pancreatic adenocarcinoma
  publication-title: Cancer Metastasis Rev
– volume: 1
  start-page: 26
  year: 2013
  end-page: 31
  article-title: T cells expressing chimeric antigen receptors can cause anaphylaxis in humans
  publication-title: Cancer Immunol Res
– volume: 126
  start-page: 2123
  year: 2016
  end-page: 2138
  article-title: CD19 CAR‐T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
  publication-title: J Clin Invest
– volume: 210
  start-page: 1125
  year: 2013
  end-page: 1135
  article-title: Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
  publication-title: J Exp Med
– volume: 112
  start-page: 1809
  year: 2015
  end-page: 1814
  article-title: Immune‐mediated antitumor effect by type 2 diabetes drug, metformin
  publication-title: Proc Natl Acad Sci USA
– volume: 19
  start-page: 1288
  year: 2000
  end-page: 1296
  article-title: Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer
  publication-title: Oncogene
– volume: 24
  start-page: 496
  year: 2001
  end-page: 499
  article-title: Overexpression of the HER‐2/neu oncogene in pancreatic adenocarcinoma
  publication-title: Am J Clin Oncol
– volume: 31
  start-page: 119
  year: 2005
  end-page: 125
  article-title: Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer
  publication-title: Pancreas
– volume: 36
  start-page: 133
  year: 2013
  end-page: 151
  article-title: Cancer regression and neurological toxicity following anti‐MAGE‐A3 TCR gene therapy
  publication-title: J Immunother
– volume: 86
  start-page: 10024
  year: 1989
  end-page: 10028
  article-title: Expression of immunoglobulin‐T‐cell receptor chimeric molecules as functional receptors with antibody‐type specificity
  publication-title: Proc Natl Acad Sci USA
– volume: 369
  start-page: 1691
  year: 2013
  end-page: 1703
  article-title: Increased survival in pancreatic cancer with nab‐paclitaxel plus gemcitabine
  publication-title: N Engl J Med
– volume: 253
  start-page: 328–
  year: 2011
  end-page: 335
  article-title: A lethally irradiated allogeneic granulocyte‐macrophage colony stimulating factor‐secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy, and immune activation
  publication-title: Ann Surg
– volume: 196
  start-page: 254
  year: 2002
  end-page: 265
  article-title: The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies
  publication-title: J Pathol
– volume: 17
  start-page: 651
  year: 2016
  end-page: 662
  article-title: Targeting tumour‐associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single‐centre, open‐label, dose‐finding, non‐randomised, phase 1b trial
  publication-title: Lancet Oncol
– volume: 90
  start-page: 17
  year: 1988
  end-page: 22
  article-title: Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma
  publication-title: Am J Clin Pathol
– volume: 28
  start-page: 26
  year: 2004
  end-page: 31
  article-title: CD8+ tumor‐infiltrating lymphocytes together with CD4+ tumor‐infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma
  publication-title: Pancreas
– volume: 8
  start-page: 786
  year: 2016
  end-page: 792
  article-title: Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer
  publication-title: World J Gastrointest Oncol
– volume: 58
  start-page: 49
  year: 2009
  end-page: 59
  article-title: Increased circulating myeloid‐derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin‐cyclophosphamide chemotherapy
  publication-title: Cancer Immunol Immunother
– volume: 200
  start-page: 297
  year: 2004
  end-page: 306
  article-title: Mesothelin‐specific CD8(+) T cell responses provide evidence of in vivo cross‐priming by antigen‐presenting cells in vaccinated pancreatic cancer patients
  publication-title: J Exp Med
– volume: 67
  start-page: 9518
  year: 2007
  end-page: 9527
  article-title: Dynamics of the immune reaction to pancreatic cancer from inception to invasion
  publication-title: Cancer Res
– volume: 44
  start-page: 46
  year: 2008
  end-page: 53
  article-title: Mesothelin targeted cancer immunotherapy
  publication-title: Eur J Cancer
– volume: 118
  start-page: 6050
  year: 2011
  end-page: 6056
  article-title: Antitumor activity and long‐term fate of chimeric antigen receptor‐positive T cells in patients with neuroblastoma
  publication-title: Blood
– volume: 3
  start-page: 16028
  year: 2016
  article-title: Next frontiers in CAR T‐cell therapy
  publication-title: Mol Ther Oncol
– volume: 191
  start-page: 4589
  year: 2013
  end-page: 4598
  article-title: Preclinical in vivo modeling of cytokine release syndrome induced by ErbB‐retargeted human T cells: identifying a window of therapeutic opportunity
  publication-title: J Immunol
– volume: 91
  start-page: 2086
  year: 2004
  end-page: 2093
  article-title: MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi‐C595 radioimmunoconjugate
  publication-title: Br J Cancer
– volume: 2
  start-page: 112
  year: 2014
  end-page: 120
  article-title: Mesothelin‐specific chimeric antigen receptor mRNA‐engineered T cells induce anti‐tumor activity in solid malignancies
  publication-title: Cancer Immunol Res
– volume: 206
  start-page: 1717
  year: 2009
  end-page: 1725
  article-title: Blockade of CTLA‐4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti‐CTLA‐4 antibodies
  publication-title: J Exp Med
– volume: 74
  start-page: 5057
  year: 2014
  end-page: 5069
  article-title: CSF1/CSF1R blockade reprograms tumor‐infiltrating macrophages and improves response to T‐cell checkpoint immunotherapy in pancreatic cancer models
  publication-title: Cancer Res
– volume: 20
  start-page: 70
  year: 2002
  end-page: 75
  article-title: Human T‐lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor
  publication-title: Nat Biotechnol
– volume: 124
  start-page: 838
  year: 2005
  end-page: 845
  article-title: Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis
  publication-title: Am J Clin Pathol
– volume: 364
  start-page: 1817
  year: 2011
  end-page: 1825
  article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
  publication-title: N Engl J Med
– volume: 368
  start-page: 1509
  year: 2013
  end-page: 1518
  article-title: Chimeric antigen receptor‐modified T cells for acute lymphoid leukemia
  publication-title: N Engl J Med
– volume: 403
  start-page: 380
  year: 2010
  end-page: 384
  article-title: Pancreatic stellate cells promote epithelial‐mesenchymal transition in pancreatic cancer cells
  publication-title: Biochem Biophys Res Commun
– volume: 6
  start-page: 1755
  year: 2008
  end-page: 1765
  article-title: Mesothelin‐induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3
  publication-title: Mol Cancer Res
– volume: 8
  start-page: 793
  year: 2002
  end-page: 800
  article-title: Tumor‐associated B7‐H1 promotes T‐cell apoptosis: a potential mechanism of immune evasion
  publication-title: Nat Med
– volume: 3
  start-page: 388
  year: 2013
  end-page: 398
  article-title: The basic principles of chimeric antigen receptor design
  publication-title: Cancer Discov
– volume: 28
  start-page: 638
  year: 2015
  end-page: 652
  article-title: T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma
  publication-title: Cancer Cell
– volume: 100
  start-page: 1243
  year: 2009
  end-page: 1247
  article-title: HER2 overexpression correlates with survival after curative resection of pancreatic cancer
  publication-title: Cancer Sci
– volume: 5
  start-page: 10949
  year: 2014
  end-page: 10958
  article-title: An NCR1‐based chimeric receptor endows T‐cells with multiple anti‐tumor specificities
  publication-title: Oncotarget
– volume: 111
  start-page: 1350
  year: 2016
  end-page: 1357
  article-title: Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre‐existing diabetes: a propensity score analysis
  publication-title: Am J Gastroenterol
– volume: 18
  start-page: 843
  year: 2010
  end-page: 851
  article-title: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
  publication-title: Mol Ther
– volume: 118
  start-page: 4817
  year: 2011
  end-page: 4828
  article-title: Safety and persistence of adoptively transferred autologous CD19‐targeted T cells in patients with relapsed or chemotherapy refractory B‐cell leukemias
  publication-title: Blood
– volume: 298
  start-page: 850
  year: 2002
  end-page: 854
  article-title: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
  publication-title: Science
– volume: 18
  start-page: 2478
  year: 2012
  end-page: 2489
  article-title: Mesothelin overexpression promotes mesothelioma cell invasion and MMP‐9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients
  publication-title: Clin Cancer Res
– volume: 104
  start-page: 531
  year: 2013
  end-page: 535
  article-title: Novel aspects of preoperative chemoradiation therapy improving anti‐tumor immunity in pancreatic cancer
  publication-title: Cancer Sci
– volume: 6
  start-page: e1273302
  year: 2017
  article-title: CAR T‐cell intrinsic PD‐1 checkpoint blockade: a two‐in‐one approach for solid tumor immunotherapy
  publication-title: Oncoimmunology
– volume: 75
  start-page: 2629
  year: 2015
  end-page: 2640
  article-title: Chemotherapy‐derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer
  publication-title: Cancer Res
– volume: 60
  start-page: 280
  year: 2006
  end-page: 284
  article-title: CD24 plays an important role in the carcinogenesis process of the pancreas
  publication-title: Biomed Pharmacother
– volume: 29
  start-page: 537
  year: 2013
  end-page: 543
  article-title: Deciphering the role of stroma in pancreatic cancer
  publication-title: Curr Opin Gastroenterol
– volume: 5
  start-page: 215ra172
  year: 2013
  article-title: PD‐1‐ and CTLA‐4‐based inhibitory chimeric antigen receptors (iCARs) divert off‐target immunotherapy responses
  publication-title: Sci Transl Med
– year: 2016
  article-title: T‐cell programming in pancreatic adenocarcinoma: a review
  publication-title: Cancer Gene Ther
– volume: 19
  start-page: 5636
  year: 2013
  end-page: 5646
  article-title: Anti‐PD‐1 antibody therapy potently enhances the eradication of established tumors by gene‐modified T cells
  publication-title: Clin Cancer Res
– volume: 8
  start-page: 349
  year: 2005
  end-page: 350
  article-title: The dual adverse effects of TGF‐beta secretion on tumor progression
  publication-title: Cancer Cell
– volume: 387
  start-page: 545
  year: 2016
  end-page: 557
  article-title: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine‐based therapy (NAPOLI‐1): a global, randomised, open‐label, phase 3 trial
  publication-title: Lancet
– volume: 9
  start-page: e96565
  year: 2014
  article-title: Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment
  publication-title: PLoS ONE
– volume: 4
  start-page: 325
  year: 2014
  article-title: Combinations of immunotherapy and radiation in cancer therapy
  publication-title: Front Oncol
– volume: 21
  start-page: 524
  year: 2015
  end-page: 529
  article-title: Heparanase promotes tumor infiltration and antitumor activity of CAR‐redirected T lymphocytes
  publication-title: Nat Med
– volume: 6
  start-page: 186
  year: 2008
  end-page: 193
  article-title: Mesothelin promotes anchorage‐independent growth and prevents anoikis via extracellular signal‐regulated kinase signaling pathway in human breast cancer cells
  publication-title: Mol Cancer Res
– volume: 5
  start-page: 207ra144
  year: 2013
  article-title: Tumor‐specific activation of an EGFR‐targeting probody enhances therapeutic index
  publication-title: Sci Transl Med
– volume: 76
  start-page: 1257
  year: 2016
  end-page: 1270
  article-title: Phase I trial of anti‐PSMA designer CAR‐T cells in prostate cancer: possible role for interacting interleukin 2‐T cell pharmacodynamics as a determinant of clinical response
  publication-title: Prostate
– volume: 9
  start-page: 145
  year: 1988
  end-page: 153
  article-title: Immunohistochemistry of carcino‐embryonic antigen in the embryo, fetus and adult
  publication-title: Tumour Biol
– volume: 17
  start-page: 4719
  year: 2011
  end-page: 4730
  article-title: Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin‐specific chimeric antibody receptor
  publication-title: Clin Cancer Res
– volume: 108
  start-page: 914
  year: 2013
  end-page: 923
  article-title: Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
  publication-title: Br J Cancer
– ident: e_1_2_10_3_1
  doi: 10.1056/NEJMoa1011923
– ident: e_1_2_10_39_1
  doi: 10.1016/j.ejca.2007.08.028
– ident: e_1_2_10_121_1
  doi: 10.1016/j.ccr.2005.10.018
– ident: e_1_2_10_102_1
  doi: 10.1056/NEJMoa1407222
– ident: e_1_2_10_143_1
  doi: 10.1158/0008-5472.CAN-13-3723
– ident: e_1_2_10_59_1
  doi: 10.1158/1078-0432.CCR-13-1862
– ident: e_1_2_10_53_1
  doi: 10.1158/1078-0432.CCR-05-0596
– ident: e_1_2_10_61_1
  doi: 10.1126/scitranslmed.3010162
– ident: e_1_2_10_115_1
  doi: 10.1172/JCI83092
– ident: e_1_2_10_42_1
  doi: 10.1074/jbc.M806776200
– ident: e_1_2_10_73_1
  doi: 10.1097/00000421-200110000-00016
– ident: e_1_2_10_82_1
  doi: 10.1007/s00534-006-1166-5
– ident: e_1_2_10_52_1
  doi: 10.1084/jem.20031435
– ident: e_1_2_10_125_1
  doi: 10.1016/j.jss.2009.05.026
– ident: e_1_2_10_13_1
  doi: 10.1073/pnas.0813101106
– ident: e_1_2_10_108_1
  doi: 10.1158/2326-6066.CIR-13-0008
– ident: e_1_2_10_28_1
  doi: 10.1016/j.jcyt.2016.07.003
– ident: e_1_2_10_46_1
  doi: 10.1016/j.lungcan.2005.03.020
– ident: e_1_2_10_104_1
  doi: 10.1097/CJI.0b013e3182829903
– ident: e_1_2_10_137_1
  doi: 10.1111/j.1752-8062.2008.00070.x
– ident: e_1_2_10_38_1
  doi: 10.1158/2159-8290.CD-15-0583
– ident: e_1_2_10_33_1
  doi: 10.1245/s10434-013-3390-y
– ident: e_1_2_10_56_1
  doi: 10.1371/journal.pone.0040157
– ident: e_1_2_10_54_1
  doi: 10.1097/MPA.0b013e318221bed8
– ident: e_1_2_10_31_1
  doi: 10.1177/1758834014564775
– ident: e_1_2_10_8_1
  doi: 10.1038/bjc.2013.32
– ident: e_1_2_10_103_1
  doi: 10.1038/mto.2016.11
– ident: e_1_2_10_122_1
  doi: 10.1016/j.ccr.2005.10.012
– ident: e_1_2_10_36_1
  doi: 10.1158/0008-5472.CAN-14-2921
– ident: e_1_2_10_17_1
  doi: 10.1200/JCO.2014.56.2025
– ident: e_1_2_10_92_1
  doi: 10.1084/jem.20130110
– ident: e_1_2_10_43_1
  doi: 10.1038/srep01870
– ident: e_1_2_10_24_1
  doi: 10.1158/2326-6066.CIR-13-0170
– ident: e_1_2_10_89_1
  doi: 10.1158/1541-7786.MCR-11-0023
– ident: e_1_2_10_84_1
  doi: 10.1038/35059110
– ident: e_1_2_10_77_1
  doi: 10.1016/j.immuni.2016.05.014
– ident: e_1_2_10_2_1
  doi: 10.1158/0008-5472.CAN-14-0155
– ident: e_1_2_10_5_1
  doi: 10.1016/S0140-6736(15)00986-1
– ident: e_1_2_10_63_1
  doi: 10.1093/ajcp/90.1.17
– ident: e_1_2_10_16_1
  doi: 10.1126/scitranslmed.3008226
– ident: e_1_2_10_18_1
  doi: 10.1056/NEJMoa1215134
– ident: e_1_2_10_30_1
  doi: 10.1002/pros.23214
– ident: e_1_2_10_64_1
  doi: 10.1136/jcp.39.6.610
– volume: 61
  start-page: 4320
  year: 2001
  ident: e_1_2_10_79_1
  article-title: Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma
  publication-title: Cancer Res
– ident: e_1_2_10_118_1
  doi: 10.1158/1078-0432.CCR-06-0369
– ident: e_1_2_10_111_1
  doi: 10.1126/scitranslmed.3006682
– ident: e_1_2_10_129_1
  doi: 10.1080/2162402X.2016.1273302
– ident: e_1_2_10_139_1
  doi: 10.1073/pnas.1417636112
– ident: e_1_2_10_141_1
  doi: 10.1158/0008-5472.CAN-11-3850
– ident: e_1_2_10_35_1
  doi: 10.1111/cas.12119
– ident: e_1_2_10_76_1
  doi: 10.1007/s002620050254
– ident: e_1_2_10_94_1
  doi: 10.1097/CJI.0b013e3181ee6675
– ident: e_1_2_10_124_1
  doi: 10.1158/0008-5472.CAN-07-0175
– ident: e_1_2_10_34_1
  doi: 10.1016/j.cellimm.2015.02.003
– ident: e_1_2_10_67_1
  doi: 10.1053/j.gastro.2012.07.017
– ident: e_1_2_10_4_1
  doi: 10.1056/NEJMoa1304369
– ident: e_1_2_10_85_1
  doi: 10.4049/jimmunol.173.4.2392
– ident: e_1_2_10_25_1
  doi: 10.1182/blood-2011-04-348540
– ident: e_1_2_10_23_1
  doi: 10.1182/blood-2010-07-294520
– ident: e_1_2_10_68_1
– ident: e_1_2_10_19_1
  doi: 10.1172/JCI80010
– ident: e_1_2_10_147_1
  doi: 10.1593/neo.11980
– ident: e_1_2_10_22_1
  doi: 10.1182/blood-2011-05-354449
– ident: e_1_2_10_91_1
  doi: 10.1158/0008-5472.CAN-14-3041
– ident: e_1_2_10_14_1
  doi: 10.1038/mt.2009.210
– ident: e_1_2_10_109_1
  doi: 10.1007/s10875-012-9689-9
– ident: e_1_2_10_131_1
  doi: 10.1038/nature14292
– ident: e_1_2_10_130_1
  doi: 10.3389/fonc.2014.00325
– ident: e_1_2_10_88_1
  doi: 10.1097/MOG.0b013e328363affe
– ident: e_1_2_10_105_1
  doi: 10.3390/ph8020230
– ident: e_1_2_10_15_1
  doi: 10.1089/hum.2013.209
– ident: e_1_2_10_128_1
  doi: 10.1158/1078-0432.CCR-13-0458
– ident: e_1_2_10_62_1
  doi: 10.1016/j.ccell.2015.09.022
– ident: e_1_2_10_96_1
  doi: 10.1158/1078-0432.CCR-11-0351
– ident: e_1_2_10_100_1
  doi: 10.1182/blood-2011-10-384388
– ident: e_1_2_10_10_1
  doi: 10.1158/2159-8290.CD-12-0548
– ident: e_1_2_10_7_1
  doi: 10.1097/00006676-200401000-00023
– ident: e_1_2_10_44_1
  doi: 10.1074/jbc.M312372200
– ident: e_1_2_10_45_1
  doi: 10.1016/j.lungcan.2005.03.020
– ident: e_1_2_10_106_1
  doi: 10.1038/nm0296-216
– ident: e_1_2_10_72_1
  doi: 10.1016/j.ejso.2009.02.013
– ident: e_1_2_10_135_1
  doi: 10.1042/BST20150291
– ident: e_1_2_10_55_1
  doi: 10.1111/j.1349-7006.2012.02214.x
– ident: e_1_2_10_132_1
  doi: 10.1371/journal.pone.0070417
– ident: e_1_2_10_12_1
  doi: 10.1038/nbt0102-70
– ident: e_1_2_10_107_1
  doi: 10.1038/nbt.2459
– ident: e_1_2_10_123_1
  doi: 10.1002/path.1027
– ident: e_1_2_10_49_1
  doi: 10.13075/ijomeh.1896.00637
– ident: e_1_2_10_37_1
  doi: 10.1158/0008-5472.CAN-14-0337
– ident: e_1_2_10_6_1
  doi: 10.1097/MD.0000000000005541
– ident: e_1_2_10_117_1
  doi: 10.1084/jem.20082492
– ident: e_1_2_10_127_1
  doi: 10.1007/s00262-008-0523-4
– ident: e_1_2_10_29_1
  doi: 10.1172/JCI85309
– ident: e_1_2_10_144_1
  doi: 10.1016/S1470-2045(16)00078-4
– ident: e_1_2_10_81_1
  doi: 10.1038/sj.onc.1203426
– year: 2016
  ident: e_1_2_10_113_1
  article-title: T‐cell programming in pancreatic adenocarcinoma: a review
  publication-title: Cancer Gene Ther
– ident: e_1_2_10_87_1
  doi: 10.1016/j.ctrv.2016.01.004
– ident: e_1_2_10_116_1
  doi: 10.1038/nm730
– ident: e_1_2_10_134_1
  doi: 10.1371/journal.pone.0007234
– ident: e_1_2_10_26_1
  doi: 10.1182/blood-2013-06-506741
– ident: e_1_2_10_60_1
  doi: 10.1371/journal.pone.0114900
– ident: e_1_2_10_140_1
  doi: 10.1038/ajg.2016.288
– ident: e_1_2_10_41_1
  doi: 10.1158/1541-7786.MCR-07-0254
– ident: e_1_2_10_65_1
  doi: 10.1159/000217555
– ident: e_1_2_10_50_1
  doi: 10.1158/1078-0432.CCR-07-0869
– ident: e_1_2_10_27_1
  doi: 10.1126/science.1076514
– ident: e_1_2_10_48_1
  doi: 10.1111/j.1349-7006.2007.00715.x
– ident: e_1_2_10_71_1
  doi: 10.1016/j.biopha.2006.06.006
– ident: e_1_2_10_58_1
  doi: 10.1158/1078-0432.CCR-11-2614
– ident: e_1_2_10_138_1
  doi: 10.1007/s00262-012-1324-3
– ident: e_1_2_10_86_1
  doi: 10.18632/oncotarget.1919
– ident: e_1_2_10_98_1
  doi: 10.1038/mt.2010.24
– ident: e_1_2_10_47_1
  doi: 10.1164/rccm.200802-258OC
– ident: e_1_2_10_70_1
  doi: 10.1158/0008-5472.CAN-06-2030
– ident: e_1_2_10_78_1
  doi: 10.1158/1078-0432.CCR-09-3169
– ident: e_1_2_10_51_1
  doi: 10.1097/SLA.0b013e3181fd271c
– ident: e_1_2_10_32_1
  doi: 10.4251/wjgo.v8.i11.786
– ident: e_1_2_10_133_1
  doi: 10.1084/jem.20101876
– ident: e_1_2_10_114_1
  doi: 10.1159/000007488
– ident: e_1_2_10_57_1
  doi: 10.1309/F1B64CL7H8VJKEAF
– ident: e_1_2_10_69_1
– ident: e_1_2_10_99_1
  doi: 10.1158/2326-6066.CIR-13-0006
– ident: e_1_2_10_90_1
  doi: 10.1016/j.bbrc.2010.11.040
– ident: e_1_2_10_110_1
  doi: 10.1126/scitranslmed.3006597
– ident: e_1_2_10_95_1
  doi: 10.1182/blood-2009-03-209650
– ident: e_1_2_10_66_1
  doi: 10.1053/j.gastro.2012.06.037
– ident: e_1_2_10_126_1
  doi: 10.1111/j.1349-7006.2012.02411.x
– ident: e_1_2_10_20_1
  doi: 10.1038/mto.2016.28
– ident: e_1_2_10_93_1
  doi: 10.1038/nm.3833
– ident: e_1_2_10_74_1
  doi: 10.1111/j.1349-7006.2009.01176.x
– ident: e_1_2_10_83_1
  doi: 10.1111/j.1477-2574.2011.00344.x
– ident: e_1_2_10_142_1
  doi: 10.1111/cas.12332
– ident: e_1_2_10_119_1
  doi: 10.1371/journal.pone.0096565
– ident: e_1_2_10_146_1
  doi: 10.1007/s10555-013-9439-3
– ident: e_1_2_10_97_1
  doi: 10.1038/mt.2013.17
– ident: e_1_2_10_136_1
  doi: 10.4161/onci.27614
– ident: e_1_2_10_145_1
  doi: 10.1016/j.ccr.2012.01.007
– ident: e_1_2_10_75_1
  doi: 10.1038/sj.bjc.6602232
– ident: e_1_2_10_120_1
  doi: 10.4049/jimmunol.182.3.1746
– ident: e_1_2_10_40_1
  doi: 10.1158/1541-7786.MCR-08-0095
– ident: e_1_2_10_80_1
  doi: 10.1097/01.mpa.0000173459.81193.4d
– ident: e_1_2_10_21_1
  doi: 10.1038/nm.1882
– ident: e_1_2_10_101_1
  doi: 10.4049/jimmunol.1301523
– ident: e_1_2_10_11_1
  doi: 10.1073/pnas.86.24.10024
– ident: e_1_2_10_9_1
  doi: 10.1111/imr.12132
– ident: e_1_2_10_112_1
  doi: 10.1126/science.aab4077
SSID ssj0009964
Score 2.4789793
SecondaryResourceType review_article
Snippet Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results...
Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results...
Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient’s own T cells to target cancer cells. The remarkable results...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 63
SubjectTerms adoptive cell therapy
Antigens, Neoplasm - immunology
Cancer surgery
CAR T cells
Carcinoembryonic Antigen - immunology
CD24 Antigen - immunology
checkpoint blockade
chimeric antigen receptor
Clinical Trials as Topic
GPI-Linked Proteins - immunology
Humans
immunotherapy
Immunotherapy, Adoptive
Mesothelin
Mucin-1 - immunology
Neoplasm Proteins - immunology
Pancreatic cancer
Pancreatic Neoplasms - immunology
Pancreatic Neoplasms - therapy
Receptor, ErbB-2 - immunology
Receptors, Antigen, T-Cell
Receptors, Natural Killer Cell - immunology
Stromal Cells - immunology
T-Lymphocytes - immunology
T-Lymphocytes - transplantation
Transplantation Conditioning
Title CAR T‐cell therapy for pancreatic cancer
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjso.24627
https://www.ncbi.nlm.nih.gov/pubmed/28346697
https://www.proquest.com/docview/1914572600
https://www.proquest.com/docview/1881774076
https://pubmed.ncbi.nlm.nih.gov/PMC5491361
Volume 116
WOSCitedRecordID wos000404555200008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1096-9098
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0009964
  issn: 0022-4790
  databaseCode: DRFUL
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFD7qBU28jA02KJQqQzygSdkSx_FFPFVlFUJdh0qR-hYljq0VoRT1Mok3fgK_cb9kx7mVaiAh7S1RThwfn3Ps7zj2Z4C3yijBpApcHMtDl5oUYy4QxtUitOzixMRevlF4xMdjMZvJzw14X-2FKfgh6gk3Gxl5f20DPE5W51vS0G-rxRmhjPAmtAn6bdiC9ofJ8Otoy7krGa3IwimXXkUs5JHz-uXd4egexry_VPJPCJuPQcMnD6r9AeyX0NPpF75yCA2dPYW9y_Ln-jM4HfQnzvT21287me8UG7N-OghqHewxCnCpHGW9ZHkE0-HFdPDRLY9ScBWlAXexW6OJsniAaW3pjJiXCE8TJZUJE88wk0qtZZLiHcGE2dg0CFOd2NLh-H5wDK1skekX4KRpStM0Zjj4MWoSLoyWgbDlCz_2FevAu6pBI1XSjNvTLr5HBUEyiVD1KFe9A29q0R8Ft8bfhLqVVaIyvFaRJaULueXW78BJ_RgDwzZQnOnFBmWE8BHbehyr9LwwYv0VxFSUMYmF8x3z1gKWdHv3STa_zsm3MZ9GzX1UMzfvvyseffpylV-8_H_RV_CYWNiQLwfuQmu93OjX8EjdrOerZQ-afCZ6pZffAewy_ko
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS-wwEB48Kkdf9Ojxsl6OVXw4CNVesmkCvoi6eFlX0RX2rbRpgop0ZVcF3_wJ_kZ_iTO96aLCgfPW0mmaycwk36TJF4B1ZZTgUvk2juV1m5kEY84XxtaiTuzinomcbKNwM2i1RKcjz4Zgu9wLk_NDVBNuFBlZf00BThPSW--soTf97qbHuBf8gBGGboT-PbJ33rhsvpPuSs5KtnAWSKdkFnK8rerlwfHoE8j8vFbyI4bNBqHG5P9V_xdMFODT2sm9ZQqGdDoNP0-K3-u_YWN359xqvz6_0HS-lW_NerIQ1lrYZ-TwUlmK_KQ3A-3Gfnv3wC4OU7AVY35gY8fGYkWIgGtNhEbciYWjPSWVqceO4SaRWss4wTsPU2ZDiRAmOxER4riuPwvDaTfV82AlScKSJOI4_HFm4kAYLX1B5Qs3chWvwd-yRUNVEI3TeRe3YU6R7IWoepipXoO1SvQuZ9f4SmipNEtYBFg_JFq6ekDs-jVYrR5jaFADRanuPqCMEC6iWyfAKs3lVqy-gqiKcS6x8GDAvpUA0W4PPkmvrzL6bcyoUXMX1czs-33Fw6OL0-xi4d9FV2DsoH3SDJuHreNFGPcIRGSLg5dg-L73oJdhVD3eX_d7fwpnfwMjPQFh
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZT9wwEB7BghAvPbi6lNKAeEBIgRxex5b6goAVx7IgWKR9ixIfAlRl0S5U4q0_ob-xv6QzuegKkJB4S5SJ4_F4PN849meADWWV4FKFLsbylsusRp8LhXWNaBG7eGATL98o3Im6XdHvy_MJ-FHthSn4IeoJN_KMfLwmBzd32u48sYbejgbbAeNBNAlTjA6RacDU_kX7qvNEuis5q9jCWSS9ilnIC3bql8fj0TOQ-Xyt5P8YNg9C7Y_vq_4n-FCCT2e36C2fYcJkczBzWv5en4etvd0Lp_f39x-azneKrVmPDsJaB8eMAl4qR1E_GS5Ar33Q2zt0y8MUXMVYGLk4sLFUESLgxhChEfdS4ZlASWVbqWe51dIYmWq8CzBltpQIYbKTECGO74eL0MgGmfkCjtaaaZ1wDH-c2TQS1shQUPnCT3zFm7BZtWisSqJxOu_iZ1xQJAcxqh7nqjdhvRa9K9g1XhJaqcwSlw42iomWrhURu34T1urH6BrUQElmBg8oI4SP6NaLsEpLhRXrryCqYpxLLDwas28tQLTb40-ym-ucfhszatTcRzVz-75e8fj48iy_WH676HeYOd9vx52j7slXmA0IQ-Rrg1egcT98MN9gWv26vxkNV8u-_g-tqgDc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CAR+T%E2%80%90cell+therapy+for+pancreatic+cancer&rft.jtitle=Journal+of+surgical+oncology&rft.au=DeSelm%2C+Carl+J.&rft.au=Tano%2C+Zachary+E.&rft.au=Varghese%2C+Anna+M.&rft.au=Adusumilli%2C+Prasad+S.&rft.date=2017-07-01&rft.issn=0022-4790&rft.eissn=1096-9098&rft.volume=116&rft.issue=1&rft.spage=63&rft.epage=74&rft_id=info:doi/10.1002%2Fjso.24627&rft.externalDBID=10.1002%252Fjso.24627&rft.externalDocID=JSO24627
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-4790&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-4790&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-4790&client=summon